TRETOQUINOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H23NO5
Molecular Weight	345.3896
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(C[C@@H]2NCCC3=C2C=C(O)C(O)=C3)=CC(OC)=C1OC

InChI

InChIKey=RGVPOXRFEPSFGH-AWEZNQCLSA-N

InChI=1S/C19H23NO5/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14/h7-10,14,20-22H,4-6H2,1-3H3/t14-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H23NO5
Molecular Weight	345.3896
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://drugs-infos.blogspot.ru/2009/07/inolin-pediatric-drops.html
Curator's Comment: description was created based on several sources, including: http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf

Trimetoquinol hydrochloride dilates bronchial muscle selectively by stimulating Beta 2-receptors. It is used for the relief of bronchoconstriction associated with bronchitis, asthmatic bronchitis and bronchial asthma. Since the concurrent use of the drug with catecholamines such as Epinephrine and Isoproterenol may induce arrythmia or cardiac arrest in some cases, concurrent use is not recommended. Adverse reactions : Palpitation may occur occasionally, and alteration of blood pressure and precordial pain may appear rarely; headache may occur occasionally; tremor, dizziness, feverish sensation may also be encountered in a rare incidence; occasionally, nausea and anorexia may appear.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2894642 \| http://www.ncbi.nlm.nih.gov/pubmed/2894642 \| www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf	Agonist 2678	7.34 null [pKi]
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10525112	Agonist 2678	6.49 null [pKi]
Beta-3 adrenergic receptor 49 Target ID: CHEMBL246 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10525112	Agonist 2678	5.43 null [pKi]

Conditions

Condition	Modality	Highest Phase	Product
Asthma 241 Sources: http://www.ncbi.nlm.nih.gov/mesh/AQ-110 http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html	Palliative	Approved 8429	Inolin Approved Use It is given as the bronchodilating agent in the management of reversible airways obstruction, as in asthma.
Chronic obstructive pulmonary disease 174 Sources: www.drugfuture.com/mt/tretoquinol-hydrochloride.pdf	Palliative	Approved 8429	Inolin Approved Use It is given as the bronchodilating agent in the management of reversible airways obstruction, as in chronic obstructive pulmonary disease.
Chronic bronchitis 51 Sources: http://www.situsobat.com/2014/04/inolin-tablet-3-mg.html	Palliative	Approved 8429	Inolin Approved Use It is used to treat chronic bronchitis.

PubMed

Title	Date	PubMed
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.	2001	11687053
Biochemical activities of trimetoquinol analogs at human beta(1)- and beta(3)-adrenergic receptors.	2001 Jan	11150922
Beta-adrenoreceptor agonists for diffuse esophageal spasm.	2002	11931538
Single-incision, minimally invasive total hip arthroplasty: length doesn't matter.	2004 Dec	15586328
Endoscopic video-assisted breast surgery: procedures and short-term results.	2006 Aug	16936445
Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial.	2006 Feb	16424525
1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diols as novel affinity and photoaffinity probes for beta-adrenoceptor subtypes.	2006 Mar 15	16431119
Intravenous and intratracheal administration of trimetoquinol, a fast-acting short-lived bronchodilator in horses with 'heaves'.	2006 Nov	17124848
Trimetoquinol: bronchodilator effects in horses with heaves following aerosolised and oral administration.	2007 May	17520971
The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study.	2008 Aug	18462423
Plasma and urinary concentrations of trimetoquinol by LC-MS-MS following intravenous and intra-tracheal administration to horses with heaves.	2008 Dec	19000271
[Yersinia psuedotuberculosis septicemia in a healthy young woman].	2008 Mar	18411766
Identification and characterization of a novel peptide ligand of Tie2 for targeting gene therapy.	2008 Mar	18330476
Eyelid localization in mantle cell lymphoma: long-lasting complete remission after surface brachytherapy.	2009 May-Jun	19688983
Errors in opioid prescribing: a prospective survey in cancer pain.	2010 Apr	20413057

Sample Use Guides

In Vivo Use Guide

3-12 mg per day (in 2-3 separate doses)

Route of Administration: Oral

In Vitro Use Guide

Pre-incubation of platelet microsomes with Trimethoquinol (10-100 ug/ml) for up to 4 min didn’t suppress production of Thromboxane A2-like activity.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:57:22 GMT 2023` Edited by `admin` on `Fri Dec 15 15:57:22 GMT 2023`
Record UNII	JIO3275WGI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TRETOQUINOL

Official Name

English

Tretoquinol [WHO-DD]

Common Name

English

S-(-)-TRETOQUINOL

Common Name

English

TRETOQUINOL, (-)-

Common Name

English

6,7-ISOQUINOLINEDIOL, 1,2,3,4-TETRAHYDRO-1-((3,4,5-TRIMETHOXYPHENYL)METHYL)-, (1S)-

Systematic Name

English

(-)-TRETOQUINOL

Common Name

English

(-)-1,2,3,4-TETRAHYDRO-1-(3,4,5-TRIMETHOXYBENZYL)ISOQUINOLINE-6,7-DIOL

Systematic Name

English

tretoquinol [INN]

Common Name

English

TRIMETHOQUINOL

Common Name

English

Classification Tree Code System Code

WHO-ATC

R03AC09